Nurix Therapeutics(NRIX)
$16.33+0.45 (+2.83%)
NRIX
Nurix Therapeutics financials statements
$16.33
At close:+0.45 (+2.83%)
Want to see NRIX full AI Analyst Report?
Nurix Therapeutics (NRIX) Ratios
612 Followers
Nurix Therapeutics Ratios
NRIX's free cash flow for Q3 2026 was $614.24M. For the 2026 fiscal year, NRIX's free cash flow was decreased by $-1.39M and operating cash flow was $615.63M. See a summary of the company’s cash flow.
| Ratios | Nov 25 | Nov 24 | Nov 23 | Nov 22 | Nov 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 |
| Quick Ratio | 7.02 | 6.46 | 3.40 | 4.52 | 4.70 |
| Cash Ratio | 2.86 | 1.15 | 0.63 | 0.91 | 1.22 |
| Solvency Ratio | -1.64 | -1.30 | -0.89 | -1.56 | -0.86 |
| Operating Cash Flow Ratio | -2.88 | -1.80 | -0.94 | -2.26 | -1.27 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -10.86 | -28.90 | -21.93 |
| Net Current Asset Value | $ 457.43M | $ 477.04M | $ 140.40M | $ 205.39M | $ 176.65M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.04 | 0.09 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.10 | 0.05 | 0.15 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.09 | 0.05 | 0.13 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.28 | 1.27 | 1.77 | 1.37 | 1.39 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | -19.89 | -32.50 | -30.16 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.64 | 0.42 | 0.56 | 0.25 | 0.30 |
| Net Debt to EBITDA | 0.78 | 0.40 | 0.16 | 0.29 | 0.58 |
| Profitability Margins | |||||
| Gross Profit Margin | 77.55% | -306.30% | -145.69% | -377.64% | -291.37% |
| EBIT Margin | -314.00% | -390.52% | -201.41% | -476.01% | -396.26% |
| EBITDA Margin | -291.55% | -375.83% | -193.45% | -465.27% | -389.57% |
| Operating Profit Margin | -340.16% | -390.52% | -201.41% | -476.01% | -396.26% |
| Pretax Profit Margin | -314.00% | -354.36% | -186.98% | -466.93% | -393.49% |
| Net Profit Margin | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% |
| Continuous Operations Profit Margin | -314.90% | -354.85% | -186.98% | -466.93% | -393.93% |
| Net Income Per EBT | 100.29% | 100.14% | 100.00% | 100.00% | 100.11% |
| EBT Per EBIT | 92.31% | 90.74% | 92.83% | 98.09% | 99.30% |
| Return on Assets (ROA) | -38.43% | -28.92% | -40.48% | -43.28% | -24.58% |
| Return on Equity (ROE) | -49.09% | -36.73% | -71.80% | -59.39% | -34.24% |
| Return on Capital Employed (ROCE) | -47.48% | -37.15% | -57.72% | -53.12% | -28.72% |
| Return on Invested Capital (ROIC) | -47.26% | -36.63% | -56.16% | -52.29% | -28.45% |
| Return on Tangible Assets | -38.43% | -28.92% | -40.48% | -43.28% | -24.58% |
| Earnings Yield | -18.05% | -13.04% | -42.59% | -29.95% | -9.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 36.37 | 96.23 | 35.12 | 4.80 |
| Payables Turnover | 1.68 | 19.30 | 29.55 | 36.43 | 17.51 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -167.72 | 0.00 |
| Fixed Asset Turnover | 1.15 | 1.19 | 1.61 | 1.31 | 1.17 |
| Asset Turnover | 0.12 | 0.08 | 0.22 | 0.09 | 0.06 |
| Working Capital Turnover Ratio | 0.16 | 0.15 | 0.34 | 0.16 | 0.12 |
| Cash Conversion Cycle | -217.09 | -8.87 | -8.56 | -1.80 | 55.27 |
| Days of Sales Outstanding | 0.00 | 10.04 | 3.79 | 10.39 | 76.12 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -2.18 | 0.00 |
| Days of Payables Outstanding | 217.09 | 18.91 | 12.35 | 10.02 | 20.85 |
| Operating Cycle | 0.00 | 10.04 | 3.79 | 8.22 | 76.12 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.88 | -2.57 | -1.50 | -3.29 | -1.97 |
| Free Cash Flow Per Share | -3.04 | -2.71 | -1.65 | -3.54 | -2.10 |
| Dividend Paid and CapEx Coverage Ratio | -17.82 | -18.61 | -9.69 | -13.05 | -14.90 |
| Capital Expenditure Coverage Ratio | -17.82 | -18.61 | -9.69 | -13.05 | -14.90 |
| Operating Cash Flow Coverage Ratio | -4.48 | -6.10 | -2.66 | -13.36 | -6.47 |
| Operating Cash Flow to Sales Ratio | -2.97 | -3.16 | -1.06 | -4.14 | -2.84 |
| Free Cash Flow Yield | -17.98% | -12.25% | -26.56% | -28.57% | -7.28% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -5.54 | -7.67 | -2.35 | -3.34 | -10.55 |
| Price-to-Sales (P/S) Ratio | 17.45 | 27.21 | 4.39 | 15.59 | 41.55 |
| Price-to-Book (P/B) Ratio | 2.72 | 2.82 | 1.69 | 1.98 | 3.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.56 | -8.16 | -3.77 | -3.50 | -13.73 |
| Price-to-Operating Cash Flow Ratio | -5.87 | -8.60 | -4.15 | -3.77 | -14.65 |
| Price-to-Earnings Growth (PEG) Ratio | -0.94 | -0.88 | 0.08 | -0.09 | 9.70 |
| Enterprise Value Multiple | -5.20 | -6.84 | -2.11 | -3.06 | -10.08 |
| Enterprise Value | 1.27B | 1.40B | 313.97M | 549.74M | 1.17B |
| EV to EBITDA | -5.20 | -6.84 | -2.11 | -3.06 | -10.08 |
| EV to Sales | 15.17 | 25.71 | 4.08 | 14.23 | 39.29 |
| EV to Free Cash Flow | -4.84 | -7.71 | -3.50 | -3.20 | -12.98 |
| EV to Operating Cash Flow | -5.11 | -8.13 | -3.86 | -3.44 | -13.85 |
| Tangible Book Value Per Share | 6.22 | 7.85 | 3.69 | 6.25 | 7.98 |
| Shareholders’ Equity Per Share | 6.22 | 7.85 | 3.69 | 6.25 | 7.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | 0.00 | 0.00 | -0.00 |
| Revenue Per Share | 0.97 | 0.81 | 1.42 | 0.79 | 0.69 |
| Net Income Per Share | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.91 | 0.93 | 0.98 | 0.99 |
| Research & Development to Revenue | 3.67 | 4.06 | 2.46 | 4.78 | 3.91 |
| SG&A to Revenue | 0.63 | 0.84 | 0.56 | 0.98 | 1.05 |
| Stock-Based Compensation to Revenue | 0.45 | 0.62 | 0.44 | 0.73 | 0.53 |
| Income Quality | 0.94 | 0.89 | 0.57 | 0.89 | 0.72 |
Currency in USD
